文｜财华社有传即将于8月15日在港交所（00388.HK）上市的生物科技公司银诺医药-B（02591.HK），超购规模已超五千倍，似乎已为其上市首日的表现提供了无尽遐想。联想到8月11日上市，上市两个交易日已上涨超过两倍的另一家生物科技公司中慧生物-B（02627.HK）的强劲表现，银诺医药无疑被市场寄予了更高的期待。银诺医药成立于2014年，是全球第三家商业化原研人源长效胰高血糖素样肽-1（...
Source Link文｜财华社有传即将于8月15日在港交所（00388.HK）上市的生物科技公司银诺医药-B（02591.HK），超购规模已超五千倍，似乎已为其上市首日的表现提供了无尽遐想。联想到8月11日上市，上市两个交易日已上涨超过两倍的另一家生物科技公司中慧生物-B（02627.HK）的强劲表现，银诺医药无疑被市场寄予了更高的期待。银诺医药成立于2014年，是全球第三家商业化原研人源长效胰高血糖素样肽-1（...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.